Aging and Senotherapeutics

Ivana Čepelak, Slavica Dodig

Department of Medical Biochemistry and Hematology, School of Pharmacy and Biochemistry, University of Zagreb, Croatia

Abstract:
One of the key mechanisms of the aging process of an organism and of the dysfunctionality and chronic diseases related with aging is the so-called cell senescence. It implies irreversible cell cycle arrest that occurs in response to different forms of cellular stress. Senescent cells that accumulate over time are viable, subject to phenotypic changes and excrete different soluble factors, and may affect adjacent cells, resulting in tissue and organ function disorders.

Since old age is an important risk factor for many diseases, the interest of the scientific community is to reduce or avoid the effects of the aging processes. Among numerous developed therapeutic strategies, the development of senotherapeutics (i.e. the targeting strategy) has a significant place and is based on the removal of senescent cells and the abolishment of their adverse effects. Although many questions are still open, based on numerous experimental studies, it is expected that the development of senotherapeutics will contribute to the healthy life of the elderly and the treatment of specific age-related diseases.

Keywords: aging; cell senescence; senotherapeutics

Sažetak:
Jedan od ključnih mehanizama procesa starenja organizma i sa starenjem povezanih disfunkcionalnosti i kroničnih bolesti je tzv. stanična senescencija (stanično starenje). Podrazumijeva nepovratni zastoj staničnog ciklusa koji se javlja kao odgovor na različite oblike staničnog stresa. Senescentne stanice koje se tijekom vremena akumuliraju, viabile su, podliježu fenotipskim promjenama i izlučuju različite topljive čimbenike, te mogu utjecati na susjedne stanice, što rezultira poremećajem funkcije tkiva i organa.

Kako je starosna dob bitan čimbenik rizika za brojne bolesti, ublažavanje ili izbjegavanje učinaka procesa starenja u fokusu je interesa znanstvene zajednice. Među brojnim terapijskim strategijama koje se razvijaju, značajno mjesto zauzima razvoj senoterapeutika, odnosno strategija ciljanja, odnosno ukljanjanja senescentnih stanica i poništavanja njihovih nepovoljnih učinaka. Premda su još uvijek otvorena brojna pitanja, temeljem brojnih eksperimentalnih istraživanja očekuje se da će razvoj senoterapeutika doprinijeti zdravom životnom vijeku starijih osoba kao i tretmanu specifičnih bolesti povezanih sa starenjem.

Ključne riječi: starenje; stanična senescencija; senoterapeutici
INTRODUCTION

The life expectancy of humans has increased significantly over the past few decades and the assumption is that this trend will continue in the future, so the aging process will have an important place in biomedical research. Since many illnesses are associated with the aging process, it is inevitable that they therefore increase the cost of healthcare systems around the world. The common goal and the challenge of a modern society is to ensure healthy aging and the general well-being of people. According to the World Health Organization (WHO), healthy aging is defined as “the process of developing and maintaining the functional ability that enables wellbeing in older age”, hence the ability to meet basic personal needs, to grow, learn and make decisions, to be mobile, to build and maintain relationships, to contribute to society, etc.

What is really aging? Why do we become elderly? How are we getting older? Is aging a disease? Are the diseases associated with aging different from aging? Is aging really inevitable? Can the aging process slow down / stop, or is aging a medical-solving problem? These and other issues are constantly present in each individual’s life. Researchers from different fields of science are trying to answer these questions.

One of the aging definitions, which includes all others, states that the aging process is a “progressive, generalized impairment of function that results in a loss of adaptive response to stress and an increasing probability of death”. Undoubtedly, the aging process, depending on the developmental age, is a physiological phenomenon with useful (transformation, adaptation) and adverse consequences, it is a leading risk factor to various pathological conditions. The aging process in some organisms is faster, in some it is slower, but always it is characterized by a reduced body condition and increased risk of dying.

Aging is a multifactorial, complex process, both on a population and on an individual level. Mnemonically, it is well described by abbreviation CUPID (Cumulative, Progressive, Intrinsic, Deleterious). How aging is a complex process, shows up to now more than 300 evolutionary and mechanistic aging theories, and it is to be expected that there will be new theories. All these theories are trying to explain why and how organisms become elderly. There are different classifications of these theories, but in general they can be divided into a) programmed theories that include genetically programmed aging, among which the best known is the theory of replicative aging, and b) damage theory, with theory of free radicals as the leading theory, that includes accumulation of unrepaired proteins, lipids and DNA damaged by free radicals. The central place in this theory have the changes in mitochondria, organelles that are necessary for almost every tissue. It has been shown that mitochondria are involved in various aspects of aging - from the reduction of functions of stem cells to cell senescence. The group of damage theory also includes the so-called “Inflamaging” theory, according to which aging is the result of a continuous low-level inflammatory process during human life.

Since none of the set theories of aging can clarify all aspects of the aging process, a new term – “deleteriome” has recently been introduced. This term implies a measure of the biological age of cells, organs or systems obtained simultaneously by measuring genomic, epigenetic changes, mutations, profiled metabolites and gene expression, which is enabled by the increase of the “omic” fields of research. Thus, the term “deleteriome” links the programmed theories and damage theories.

The results of numerous researches in the field of aging also provided the basis for the development of various therapeutic strategies. The discovery of new compounds that would slow down the aging process, ie prolong the healthy life span and test the potential anti-aging effects of already licensed drugs in the center is of interest to numerous scientists. In the world, a growing number of drug-based companies are established based on one of the set different strategies. The aim of this review is to nearly describe the phenomenon of cellular senescence, one of the supposed causes of aging, and a therapeutic strategy based on this phenomenon. In search of scientific and review papers on the PubMed free search engine, following key words were used: cell senescence, aging, lifespan, senotherapeutics. Articles published in English between 2004 and 2019 were included, and were selected according to relevance to the topic.

HALMARKS OF AGING PROCESS

The aging process of the organism is reflected in the multiple anatomical and functional characteristics of organisms and organic systems such as cardiovascular, gastrointestinal, orphangeal, pulmonary, nervous, endocrine, skin, etc. At the molecular level, there are numerous changes as aging process characteristics, such as: a) genomic instability due to the numerous possibilities of DNA damage on the one hand (eg. free radicals, environmental UV-induced mutagens, chemical modifications) and an intrinsic inefficient repair systems of nuclear and mitochondrial DNA, antioxidative enzymes, degradation of damaged DNA and proteins, programmed cell death, etc., on the other hand. b) epigenetic changes such as histone modifications (eg acetylation, phosphorylation), methylation of DNA, non-coding RNAs, etc. c) telomeres shortening, whereby the degree of telomeres shortening is in correlation with the risks of diseases associated with the aging; d) mitochondrial dysfunction resulting in changes in regulation of various signal processes; e) disturbance of clearance and degradation of damaged protein by proteasomes or autophagy; f) derangement of pathways of nutrient recognition including factors such as IGF-1 (Insulin like growth factor-1), mTOR (mammalian target of rapamycin) and NAD-dependent sirtuins; g) stem cell exhaustion; h) reduced regeneration capacity during aging and in age-related diseases; i) changed intercellular communication; j) cellular senescence – one of the basic causes of aging and the most frequently observed hallmark of aging.
**Cell Senescence**

Cell senescence is a phenomenon / process involved in normal tissue homeostasis, eg. embryonic development and remodeling of tissues\(^ {23, 24} \), and in various age-related pathological conditions\(^ {25} \), and is also a potent anticancer mechanism, because it limits the replication of pre-neoplastic cells\(^ {26} \). According to present knowledge, cell senescence implies stable, irreversible stopping of the cell cycle and is induced by the activation of two tumor suppressor pathways: p53/p21 and p16INK4a/pRb (retinoblastoma protein)\(^ {27} \). However, recently, in the scientific literature, there are also in vitro studies that give indications of the possible reversibility of the process of cell senescence or replication\(^ {28, 29} \). As it is assumed for now, this could happen if the cells are in the initial stages of the aging process, i.e. in the state of stopping the cell cycle. Examinations are mostly carried out on tumor cell cultures and for the time being it is not clear what is happening in vivo, so that a further concept of irreversible cell cycle arrest can be considered acceptable.

The process of cell senescence may be caused by various stressors, including mitochondrial dysfunction, telomeric erosion, DNA damage, oxidative stress and other causes. Senescent cells have been morphologically altered (change in volume, change of chromatin organization, i.e. the generation of Senescence-Associated Heterochromatin Foci, SAHF), have increased activity of senescence-associated alpha-galactosidase (SA-alpha-gal) and secrete a large number of proinflammatory cytokines, chemokines, matrix metalloproteinases, MMPs, various growth factors - alltogether referred as proteins secreted into the extracellular space, known as "secretome". Thus, the so-called Senescence Associated Secretory Phenotype (SASP)\(^ {28} \) is created. These cells may have adverse effects on neighboring cells that are not in the process of senescence, and may even contribute to the creation of tumors and other age-related diseases\(^ {29, 30} \). However, the hallmarks of senescent cells may differ significantly depending on cell type, cell senescence trigger, expression of senescence markers, secretion of different SASP factors, use of different cell apoptotic pathways (Senescence Cell Apoptotic Pathways, SCAP), etc.\(^ {31, 32} \).

The secreted pro-inflammatory cytokines further create conditions for so-called "sterile inflammation" of low level, which contributes to the theory of inflammatory aging i.e. "Inflamm-aging"\(^ {23} \). In addition, the feature of these cells is the suppression of the apoptosis process\(^ {33} \). Senescent cells are normally removed by neutrophils, macrophages and natural killer cells (NK)\(^ {34} \). However, cells can retain such a senescent status for years and accumulate. Accumulated cells that are in the process of senescence, damage the function of certain organs, but not necessarily with the same degree and speed for all organs. Their accumulation is significantly associated with the most commonly occurring disease during aging, affecting the average lifespan\(^ {35} \). Figure 1 shows the inductors, mediators and effects of senescent cells.

**Anti-senescence Strategies**

Manipulation with the aging process and attempts to prolong the life of a healthy life, respectively, are a permanent challenge for scientists - gerontologists and people in general. Significant correlation of the aging process with age-related diseases that are the leading cause of death in the world (malignant, cardiovascular, neurodegenerative) is the basis of many scientific studies of the causes and mechanisms of the aging process as well as possible therapeutic approaches. It is considered that manipulation with the basic mechanisms of the aging process could delay the appearance of various chronic diseases. In accordance with the various molecular characteristics of aging, such studies...
include the study of therapeutic potential including antioxidants, telomerase-activating compounds, immunosenscent drugs, nutraceuticals, reprogramming of stem cells, senotherapeutics, autophagy induction, finding the specific presentation of aging-related diseases and integrating of numerous data obtained by "omics" techniques, organ transplants, treatment with stem cells, or young blood/plasma rejuvenation, etc. \[36, 37\]. Investigations of the mentioned anti-aging strategies as well as general research of the aging process are, for the time being, mostly experimental in nature and are mainly focused on aging model systems. Because of moral and ethical principles in human studies, clinical research in literature is significantly less delineated. The general impression is that scientists biogerontologists increasingly perceive that anti-aging strategies directed at one molecule are limited; they consider that the dynamic, networked nature of the life process, which involves transformations and adaptations to survival and health, is at the same time neglected. Therefore, interventions/strategies that enhance homeodynamics are also considered. These strategies include nutrition, eg. intermittent hunger, Mediterranean diet, phytochemicals, physical and mental activity (common term - hormesis) \[38\]. One of the more common research strategies is the development and application of senotherapeutics, that is the main topic of this review.

Table 1. Examples of senolytics and senomorphics and their target molecules/pathways

<table>
<thead>
<tr>
<th>Compound</th>
<th>Target / Pathway</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SENOLYTICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABT 737</td>
<td>BCL-2 family (BCL-2, BCL-XL, BCL-W)</td>
<td>43</td>
</tr>
<tr>
<td>ABT-263 (navitoclax)</td>
<td>BCL-2 family (BCL-2, BCL-XL, BCL-W)</td>
<td>44</td>
</tr>
<tr>
<td>Dasatinib + Quercetin</td>
<td>Pan-receptor tyrosine kynase / Multiple pathways</td>
<td>45, 46</td>
</tr>
<tr>
<td>Geldanamycin, tenesipimycin (17-AAG)</td>
<td>HSP90</td>
<td>47, 48</td>
</tr>
<tr>
<td>Fisetin</td>
<td>PI3K/AKT</td>
<td>49</td>
</tr>
<tr>
<td>Piperlongumine</td>
<td>Multiple pathways</td>
<td>50</td>
</tr>
<tr>
<td>FOXO4-DRI peptide</td>
<td>p53 / p21 / serpin</td>
<td>51</td>
</tr>
<tr>
<td><strong>SENOMORFICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NBD peptide</td>
<td>IKK / NFB pathway</td>
<td>52</td>
</tr>
<tr>
<td>JAK inhibitor (ruxolitinib)</td>
<td>JAK (Janus kynase) pathway</td>
<td>53</td>
</tr>
<tr>
<td>ESC-CM</td>
<td>PDGF / FGF pathway</td>
<td>54</td>
</tr>
<tr>
<td>Mmu-miR-291a-3p</td>
<td>TGFBR2 / p21 pathway</td>
<td>55</td>
</tr>
</tbody>
</table>
**Senotherapeutics**

It has been shown that accumulation of senescent cells has a causal role in the aging of organs and organisms, and in age-related diseases. Therefore, most therapeutic approaches to the slowing down of various aging phenotypes and related comorbidities are based on preventing the accumulation and elimination of senescent cells with so-called senotherapeutics.

The fundamental mechanisms of activity of senotherapeutics include a) on one hand, selective killing of senescent cells (senolytics), where the main goals are the biological pathways of cell senescence processes; b) on the other hand, the suppression of SASP factors (senomorphics), i.e., the prevention of possible pro-inflammatory effect by targeting regulators and effectors of SASP [59, 60]. For both strategies already there are convincing results obtained on experimental model systems. In the development of senotherapeutics there is also c) a strategy to stimulate the immune response to the senescent cells which should result in their removal from the tissue [61, 62].

The main positions of the activity of the senotherapeutics are shown schematically in Figure 2, and in Table 1, are examples of the group of senolitics and senomorphyc compounds, some of which are described in more detail below.

Within the previously mentioned strategy c) - stimulation of senescent cell clearance by the immune system - the most commonly mentioned is the potential use of anti-DPP4 (cell surface protein CD26 or dipeptidyl peptidase 4, DPP4) antibody [63] and monoclonal antibody to CD97 as targets for the promotion of antibody-dependent cell-mediated cytotoxicity (ADDC) - dependent on antibody to senescent cells.

There are several classes of senolitics which include, for example, BCL-2 family proteins, heat shock proteins (HSP90) inhibitors, p53 / p21 and PI3K / AKT pathways inhibitors, receptor kinase inhibitors, histone deacetylase (HDAC) inhibitors, natural compounds, etc. Currently, the most interesting informations are about senolitics directed against members of the BCL-2 protein family, eg. BCL-W and BCL-XL, thus targeting the resistance of senescent cells to apoptosis, so that their destruction leads to the activation of programmed cell death and changes in the autophagy process. The first described senolitics were dasatinib (under the name SPRYCEL was used in the treatment of adult patients with chronic myeloid leukemia; its targets are several protein tyrosine kinases (eg. BCR/Abl c-KIT and some members of Src family), and herbal flavonoid quercetin involving the PI3K / AKT pathways as a molecular target [60, 61]. Dasatinib effectively reduces the viability of senescent cells in vitro and is also confirmed by its in vivo effectiveness. The combination of these compounds with senolytic action has also been used in investigations.

Navitoclax (i.e. ABT 263) is considered like senotherapeutic of powerful senolytic activity [42]. It is directed to inhibition of specific BCL-XL and BCL-W members of the family of BCL-2 apoptotic proteins. Navitoclax is also used in the treatment of some malignant conditions [62], but its use is limited due to adverse thrombocytopenic and neutropenic effects. Navitoclax analogs such as A1331852, A1155453, ABT 737 also target members of the BCL-2 protein family in both in vitro and in vivo model [42, 49]. In addition to quercetin, the therapeutic potential of other phytochemicals, such as flavonol fisetin and piperlongumine alkaloids, is also examined. The mechanism of action of the fisetin includes the PI3K / AKT / mTOR pathway, and the piperlongumine appears to include the NF-κB pathway [63]. According to literature, these compounds also exhibit senolytic and senomorphific activity, depending on the type of cells used in the study [64].

Of the natural compounds in the literature are also mentioned flavonoids kaempferol, apigenin, some compounds from the polyketide group and resveratrol [42].

The potential for senolytic activity is shown by inhibitors such as HSP90, geldanamycin, benzoquinone antineoplastic antibiotic and its analogs 17-AAG and 17-DMAG [46], an inhibitor of interactions of MDM2 / p53 proteins, as well as UBX0101, a small molecule that is already in phase 1 clinical trial in patients with osteoarthritis of the knee [64]. Furthermore, the senolytic activity of HDAC inhibitor - panobinostat, was demonstrated in senescent lung cancer cells and in the cell line of head and neck squamous cell carcinoma [65]. Panabinostat inhibits the interaction of FOXO4 and p53 and induces apoptosis in the IMR90 population, as well as in other types of senescent cells [1].

As already mentioned, senescent cells differ regarding to their characteristics, in concordance to specific cellular or tissue factors, for example expression of different markers, secretion of various SASP factors, and using different SCAP pathways. Therefore it can be assumed that other classes of senolitics will be discovered in the future, and that the combination of senotherapeutics will be more acceptable for the elimination of senescent cells from different tissues in vivo [60, 66].

Initial studies with senolitics are promising but there is no doubt that there are still many unknowns about their effectiveness. According to research on the osteoarthritis model, it has been shown that after discontinuation of senolitics, senescent cells may reappear [64].

A group of senotherapeutics that suppresses or modulates secretory phenotypes without inducing apoptosis and in a certain way interferes with “inflammaging” i.e. with senoinflammation are senomorphic drugs. These are, for example, compounds targeting senoinflammation, telomerase activators [67], mimetics of caloric restriction [67], activators of sirtuins [68] and autophagy [69], mTOR inhibitors [70], antioxidants and other compounds. As indicated in Table 1, the mechanisms of the activity of the senomorphic drugs include inhibitors of NF-κB and IκB kinase (IKK) [42], Janus kinase pathway inhibitors (JAK) [43], inhibitors of PDGF / FGF pathway and TGFBR2 / p21 pathway [42]. It has been shown that rapamycin, a drug currently used to suppress immunity in transplanted organ patients, acts as a SASP suppressant, using a mechanism that includes the inhibition of mTOR kinase, associated
with the inclusion of Nrf2-dependent and independent modules. Senomorphic potential is further attributed to some herbal compounds such as quercetin-3-O-beta-D glucuronide, juglalin and quercetagetin 3,4′-dimethyl ether.

As already mentioned, one of the ways of removing senescent cells to maintain tissue homeostasis in physiological, pathological and aging conditions is also cooperation with immune system. As an alternative therapeutic approach to the removal of senescent cells, an immune therapy strategy, i.e., antibody-mediated targeted drug delivery to senescent cells, is also established. It is also considered that immunotherapeutics for malignant diseases that are already in development could also be used for targeting senescent cells in the aging process and with aging-related diseases (Alzheimer’s, diabetes, pulmonary fibrosis, and other diseases). Expression of DPP4 on the membranes of senescent fibroblast was revealed in recent studies by Kim EC. et al. Also, it was highlighted the possibility of the use of DPP4 as a target for the promotion of antibody-dependent cell-mediated cytotoxicity against senescent cells.

Another goal of the immunotherapy strategy is the expression of the NKG2D receptor (Natural killer group 2D) on senescent cells, recognized by NK cells that also remove them. The tumor cell removal strategies are also developed on this principle.

In addition to investigations that, based on the new molecular knowledge of senescent cells and mechanisms of their formation, have the goal of detecting appropriate therapeutic goals, there is also a recent investigation of already existing licensed drugs such as senolytics or senomorphic compounds. Hence, these drugs would have an additional purpose. Namely, animal model testing, by the implementation of new bioinformatics approaches, has shown that some existing drugs are effective in prolonging life expectancy. Presently, this group of therapeutics includes, for example, multipurpose drug ruxolitinib, antineoplastic panobinostat, glucocorticoids, opioid loperamide, antipsychotic fluspirilen, antidiabetics metformin and acarbose, imunotherapy strategy is the expression of the NKG2D receptor (Natural killer group 2D) on senescent cells, recognized by NK cells that also remove them. The tumor cell removal strategies are also developed on this principle.

In conclusion, although knowledge in the field of investigations of aging, particularly the role of cell senescence in the aging process of the organism, has been extended to the molecular level in recent years, it can be said that they are still almost at the very beginning and far from complete understanding. In the future, many new discoveries are expected and an integrative approach will be needed for scientists from the fields of genetics, biology and evolution.

Can elimination of senescent cells be an intervention that will significantly extend human life? Detection and development of senotherapeutics is definitely a new and very promising field of drug research because today, along with traditional methodologies (eg. transgenic animals, in vivo models of illness etc.), various new technological approaches are available, such as sophisticated chemistry biology techniques, repurpose of already existing drugs, bioinformatics. Due to the numerous possible overlapping of the mechanisms of functioning, caution is required when interpreting their actions, selectivity and specificity and ultimately the efficacy of senotherapeutics. It should also be borne in mind that senescent cells, in addition to adverse effects, also have physiological functions, and that massively removing of such cells could disrupt the integrity of a tissue.

For now, there are insufficient knowledge on the links between molecular, cellular and physiological aspects of the removal of senescent cells. Therefore, the question of whether the elimination of senescent cells can be effective in the extension of life span remains open. It is indisputable that the scientific field of aging testing and age-related diseases as well as the field of development of senotherapeutics will further meet with numerous challenges.

Conclusion

Although knowledge in the field of investigations of aging, particularly the role of cell senescence in the aging process of the organism, has been extended to the molecular level in recent years, it can be said that they are still almost at the very beginning and far from complete understanding. In the future, many new discoveries are expected and an integrative approach will be needed for scientists from the fields of genetics, biology and evolution.

Can elimination of senescent cells be an intervention that will significantly extend human life? Detection and development of senotherapeutics is definitely a new and very promising field of drug research because today, along with traditional methodologies (eg. transgenic animals, in vivo models of illness etc.), various new technological approaches are available, such as sophisticated chemistry biology techniques, repurpose of already existing drugs, bioinformatics. Due to the numerous possible overlapping of the mechanisms of functioning, caution is required when interpreting their actions, selectivity and specificity and ultimately the efficacy of senotherapeutics. It should also be borne in mind that senescent cells, in addition to adverse effects, also have physiological functions, and that massively removing of such cells could disrupt the integrity of a tissue.

For now, there are insufficient knowledge on the links between molecular, cellular and physiological aspects of the removal of senescent cells. Therefore, the question of whether the elimination of senescent cells can be effective in the extension of life span remains open. It is indisputable that the scientific field of aging testing and age-related diseases as well as the field of development of senotherapeutics will further meet with numerous challenges.
Author contributions: All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Literature:


